Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Prurigo nodularis is skin condition characterized by itchy firm lumps on the skin. It affects people from all ages but mainly adults aged 20-60 (males and females). It has been associated with diseases including iron deficiency anemia, chronic renal failure, gluten enteropathy, HIV infection, and others, however the actual cause of this skin condition is unknown.

Rising incidences of such skin infections are expected to drive the market growth during the forecast period. For instance, according to the Journal of American Academy of Dermatology (JAAD) 2020, the prevalence of Prurigo nodularis ranges from 36.7 to 43.9 per 100,000 population in the U.S.

The global prurigo nodularis therapeutics market is estimated to be valued at US$ 824.4 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Figure 1. Global Prurigo Nodularis Therapeutics Market Share (%) in Terms of Value, By Region, 2021

Prurigo Nodularis Therapeutics  | Coherent Market Insights

Increasing drug approvals are expected to drive the market growth over the forecast period.

For instance, in 2019, Galderma S.A. a pharmaceutical company focused on dermatological treatments and skin care products, has received the U.S. Food and Drug Administration (FDA) breakthrough therapy designation for its investigational therapy drug Nemolizumab, for the treatment of pruritus associated with prurigo nodularis.

request-sample

Prurigo Nodularis Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2021: US$ 824.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2021 to 2028
Forecast Period 2020 to 2028 CAGR: 4.2% 2028 Value Projection: US$ 1,099.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Corticosteroids, Capsaicin Cream, Antihistamines, Anticonvulsants, Others
  • By End User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc. and Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.

Growth Drivers:
  • Rising Incidence of  Prurigo nodularis cases
  • Increasing Product Approvals And Launches
Restraints & Challenges:
  • Availability of alternative treatment options

Figure 2. Global Prurigo Nodularis Therapeutics Market Share (%), by Product Type, 2021

Prurigo Nodularis Therapeutics  | Coherent Market Insights

Global Prurigo Nodularis Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets

Moreover, in May 2020, the Government of India announced relief for daily wage workers and construction workers for an amount of US$ 13.3 per person of all states and union territories

Furthermore, the Brazilian government announced the economic assistance to the Brazilian population to fight against the economic crises such as unemployment and others observed in Brazil. According to the Ministry of Economy, Public Banks and the Central Bank, Brazil in March 2020, the Brazil government released the economic stimulus package, which involves the disbursement of funds to the following conditions-

  • Salary allowances and salary benefits up to US$ 2.5 billion and US$ 9.2 billion respectively to the individuals suffering from unemployment and financial crisis
  • Relaxation in the labor laws to maintain the jobs of common people in Brazil
  • Temporary reduction on the TAX

Moreover, the healthcare facilities are taking initiatives to support the COVID-19 vaccination drives in India by focusing on partnership with the Government of India to facilitate the COVID-19 vaccination drive from the Healthcare facilities.

For instance, in January 2021, Amrita Institute of Medical Sciences (AIMS) announced the partnership with Kerala Government, to facilitate the COVID-19  drive in Kerala

Global Prurigo Nodularis Therapeutics Market Restraints

The shortage of skilled healthcare professionals and availability of alternative treatment options are the major factors expected to hinder growth of the global prurigo nodularis therapeutics market. For instance, Pimecrolimus topical agent is as effective as a hydrocortisone treatment and is offered as an alternative topical treatment option that may be implemented in a long-term regimen.

Moreover, phototherapy can be used for the treatment of several inflammatory skin conditions and is also a therapeutic alternative for patients with prurigo nodularis. These factors act as the restraints for the global prurigo nodularis therapeutics market.

Key Players

Major players operating in the global prurigo nodularis therapeutics market Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc. and Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.

Prurigo Nodularis is skin disease that causes hard and itchy lumps on skin, which usually appears on the arms or legs. Prurigo nodularis is a rare disease and currently, the treatment of the disease is still in research and development process. Treatments may include topical, oral, and intralesional corticosteroids; phototherapy; antihistamines; anxiolytics; opiate receptor antagonists; and thalidomide.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global Prurigo nodularis therapeutics market. For instance, in October 2020, Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its Vixarelimab drug for the treatment of pruritus associated with prurigo nodularis.

Key features of the study:

  • This report provides in-depth analysis of the global prurigo nodularis therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global prurigo nodularis therapeutics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Prurigo nodularis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prurigo nodularis therapeutics market.

Detailed Segmentation:

  • Global Prurigo Nodularis Therapeutics Market, By Product Type:
    • Corticosteroids
    • Capsaicin Cream
    • Antihistamines
    • Anticonvulsants
    • Others
  • Global Prurigo Nodularis Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Prurigo Nodularis Therapeutics Market, By Region:
    • North America
      • By Product Type
        • Corticosteroids
        • Capsaicin Cream
        • Antihistamines
        • Anticonvulsants
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product Type
        • Corticosteroids
        • Capsaicin Cream
        • Antihistamines
        • Anticonvulsants
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type
        • Corticosteroids
        • Capsaicin Cream
        • Antihistamines
        • Anticonvulsants
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Corticosteroids
        • Capsaicin Cream
        • Antihistamines
        • Anticonvulsants
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type
        • Corticosteroids
        • Capsaicin Cream
        • Antihistamines
        • Anticonvulsants
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Corticosteroids
        • Capsaicin Cream
        • Antihistamines
        • Anticonvulsants
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bayer AG *
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Services, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Celgene Corporation
    • VYNE Therapeutics Inc.
    • Trevi Therapeutics Inc.
    • Galderma SA
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co. Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Market Trends
    • Impact Analysis
    • Pest Analysis
    • Product Portfolio Analysis
    • Company Market Share Analysis
    • Regulatory scenario
    • Key Development
    • Pipeline Analysis
  4. Global Prurigo Nodularis Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Epidemiology
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
  5. Global Prurigo Nodularis Therapeutics Market, By Product Type, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Capsaicin Cream
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Antihistamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Anticonvulsants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  6. Global Prurigo Nodularis Therapeutics Market, By Distribution Channel, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  7. Global Prurigo Nodularis Therapeutics Market, By Region, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
    • North America
      • Market Size and Forecast, By Product Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Market Share Analysis
      • Bayer AG *
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson Services, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • VYNE Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Trevi Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Galderma SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co. Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 27 market data tables and 25 figures on "Prurigo Nodularis Therapeutics Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The market size is estimated to be valued at US$ 824.4 million in 2021 and is expected to exhibit a CAGR of 4.2% between 2021 and 2028.
Rising incidence of prurigo nodularis and increasing product approvals & launches are expected to drive the market growth over the forecast period.
Corticosteroids segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Factors hampering growth of the market includes availability of alternative treatment options.
Major players operating in the market Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc. and Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner